SCHEMBL5483665

SCHEMBL5483665

Cn1c(OCCc2cnn(-c3cccc(Cl)c3)n2)nnc1-c1ccncc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.46
KCNH2 Q12809 2/20 0.43
MAPK1 P28482 1/20 0.42
GRM5 P41594 3/20 0.41
LMNA P02545 2/20 0.38
MAPT P10636 1/20 0.38
GAA P10253 2/20 0.37
HTT P42858 1/20 0.37
FLT3 P36888 2/20 0.36
GSK3B P49841 2/20 0.36
HRH2 P25021 1/20 0.36
HRH1 P35367 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
PKM P14618 1/20 0.35
TACR1 P25103 1/20 0.35
NPC1 O15118 1/20 0.34
TSHR P16473 1/20 0.34
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5739345 0.84 MEN1 (0.48) MEN1ALDH1A1KMT2AKCNH2MAPK1
SCHEMBL2889471 0.79 ALDH1A1 (0.48) MEN1ALDH1A1KMT2AKCNH2MAPK1
SCHEMBL5483661 0.78 KCNH2 (0.57) MEN1ALDH1A1KMT2AKCNH2MAPK1
SCHEMBL5480910 0.78 KCNH2 (0.57) MEN1ALDH1A1KMT2AKCNH2MAPK1
SCHEMBL5739569 0.76 GRM5 (0.46) MEN1ALDH1A1KMT2AKCNH2GRM5
Sulfuric Acid SCHEMBL5483332 0.75 KCNH2 (0.49) MEN1ALDH1A1KMT2AKCNH2MAPK1
SCHEMBL2895780 0.71 GRM5 (0.73) MEN1ALDH1A1KMT2AKCNH2MAPK1
SCHEMBL2895294 0.71 GRM5 (0.73) MEN1ALDH1A1KMT2AKCNH2MAPK1
SCHEMBL2895291 0.71 GRM5 (0.73) MEN1ALDH1A1KMT2AKCNH2MAPK1
SCHEMBL5822525 0.69 MAPK1 (0.45) MEN1ALDH1A1KMT2AKCNH2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185178-A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists AATRAZENECA AB (SE) 2007-08-09 US claimed
US-20060019997-A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-01-26 US claimed
EP-2672971-A1 METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE Pharmalundensis AB (SE) 2013-12-18 EP disclosed
WO-2012108831-A1 METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE REDECO CHEM AB (SE) 2012-08-16 WO disclosed
US-20070185178-A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists AATRAZENECA AB (SE) 2007-08-09 US disclosed
US-20060019997-A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019997-A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists GRM3, GRIN3A, GRM1 MEN1 1773/4885ALDH1A1 3228/4885KMT2A 2087/4885
US-20070185178-A1 Triazole compounds and their use as metabotropic glutamate receptor antagonists GRM5, GRM3, GRIK5 MEN1 3645/4885ALDH1A1 3599/4885KMT2A 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.